WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--March 7, 2006--On the fifth anniversary of the announcement of its worldwide HIV/AIDS pricing policy, Merck & Co., Inc.(1) today further reduced the price of its HIV/AIDS medicine, STOCRIN (efavirenz), in the least developed countries of the world and those hardest hit by the epidemic. The price of the 600 mg formulation of STOCRIN has been reduced by 20 percent to US $0.76 per day, or US $277.40 per patient per year, from $0.95 per day. The 200 mg formulation of STOCRIN has been reduced by 22 percent to US $0.36 per capsule, or $1.08 per day and about US $394.20 per patient per year, from $0.46 per capsule. Merck is lowering the price of these formulations of STOCRIN due to new efficiencies and cost savings resulting from improved manufacturing processes.
